Beta cell regeneration after single-round immunological destruction in a mouse model by unknown
ARTICLE
Beta cell regeneration after single-round
immunological destruction in a mouse model
Jason M. Tonne & Toshie Sakuma & Miguel Munoz-Gomez &
Moustafa El Khatib & Michael A. Barry & Yogish C. Kudva &
Yasuhiro Ikeda
Received: 21 August 2014 /Accepted: 26 September 2014 /Published online: 23 October 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Achieving a better understanding of beta
cell regeneration after immunological destruction is cru-
cial for the development of immunotherapy approaches
for type 1 diabetes. In previous type 1 diabetes models,
sustained immune activation eliminates regenerating beta
cells, thus limiting the study of the regenerative capacity
of beta cells upon immunological destruction. Here, we
employed an adeno-associated virus 8 (AAV8) vector
for beta cell-targeted overexpression of a foreign antigen
to induce single-round immunological destruction of
existing beta cells.
Methods Young and aged C57BL/6J mice were treated with
AAV8 vectors expressing the foreign antigen luciferase. Islet
inflammation and regeneration was observed at 3, 6, 10 and
22 weeks post-AAV delivery.
Results In young C57BL/6Jmice, robust humoral and cellular
immune responses were developed towards antigen-
expressing beta cells, leading to decreased beta cell mass.
This was followed by beta cell mass replenishment, along
with enhanced proliferation of insulin-positive cells, re-
cruitment of nestin/CD34-positive endothelial cells, dis-
placement of alpha cells and mobilisation of cytoplas-
mic neurogenin 3-positive cells. Mice with recovering
beta cells showed normal or reduced fasting blood glu-
cose levels and faster glucose clearance than controls.
Although aged mice demonstrated similar responses to
the treatment, they initially exhibited notable islet scar-
ring and fluctuations in blood glucose levels, indicating
that beta cell regeneration is slower in aged mice.
Conclusions/interpretation Our hit-and-run, beta cell-targeted
antigen expression system provides an opportunity to monitor
the impact of single-round immunological beta cell destruc-
tion in animals with diverse genetic backgrounds or ageing
status.
Keywords AAV vector . Beta cell proliferation . Beta
cell regeneration . Prediabetes . Type 1 diabetes
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In individuals susceptible to type 1 diabetes, exposure to
environmental triggers is thought to induce abnormal activa-
tion of cellular and humoral immune responses against beta
cells, leading to the initiation of beta cell destruction. The
continuing destruction of beta cells results in the progressive
reduction of insulin-secreting capacity [1]. At the time of
clinical presentation of type 1 diabetes, approximately 60–
90% of the beta cells are estimated to be destroyed or dys-
functional [2]. Notably, several studies have demonstrated
direct evidence of beta cell proliferation in early-onset type 1
diabetes [3, 4]. The spontaneous recovery of beta cell function
in some patients with early-onset type 1 diabetes also suggests
that beta cells retain their regenerative capacity in type 1
diabetes [5]. Nevertheless, primarily because of the technical
difficulties involved in monitoring beta cell mass in type 1
diabetic patients, the capacity for beta cell regeneration fol-
lowing immunological beta cell destruction has not been
determined.
A better understanding of beta cell regeneration during or
after immunological destruction may lead to the development
of a curative type 1 diabetes therapy. Existing mouse models
of type 1 diabetes, such as spontaneous or adoptive transfer-
induced type 1 diabetes, based on NOD mice, have been
widely used to study type 1 diabetes pathogenesis. In NOD
mice, an increased rate of beta cell proliferation is seen prior to
a significant decline in beta cell mass, with the highest levels
of proliferating beta cells (3% Ki67 positive) being found at
the onset of hyperglycaemia [6, 7]. Several combination ther-
apies can reverse type 1 diabetes in NOD mice, indicating the
possible recovery of endogenous insulin production in this
type 1 diabetes model [8–12]. However, sustained autoimmu-
nity towards beta cells generally results in the rapid elimina-
tion of regenerating beta cells, presenting a major barrier to
monitoring beta cell regeneration capacity in type 1 diabetes
models.
In this study, we employed an adeno-associated virus 8
(AAV8) vector for beta cell targeted, transient overexpression
of a foreign antigen (firefly luciferase) and induced single-
round immunological destruction of existing beta cells in
young and aged mouse groups. Since non-integrating AAV
vector DNAs are rapidly degraded in dividing cells [13],
newly regenerated beta cells (from proliferation of either beta
or progenitor cells) do not express the target antigen, thus
enabling extensive characterisation of beta cell regeneration
in the absence of sustained beta cell destruction.
Methods
For detailed methods, see the electronic supplementary
material (ESM) Methods. A summary is given below.
Mice All studies were approved by the Mayo Clinic
Institutional Animal Care and Use Committee. Male
C57BL/6J mice were purchased from the Jackson
Laboratory (Bar Harbor, Maine, USA). In vivo luciferase
imaging was conducted as previously described [14].
Fasting blood glucose levels were monitored using the
FreeStyle Lite Blood Glucose Monitor (Abbott Laboratories,
Chicago, Illinois, USA). Glucose tolerance tests were con-
ducted by fasting the mice for 4–5 h, followed by i.p. delivery
of 2 g/kg D-glucose in a 30% PBS solution. Blood glucose
was checked after 0, 30, 60, 90 and 120 min.
Cells 293T cells were maintained in DMEM supplemented
with 10% calf serum, 50 U/ml penicillin and 50 μg/ml strep-
tomycin. Cells were cultured at 37°C with 5% CO2.
Plasmids The 1.13 kbp mouse insulin 2 promoter (mIP2) [15]
was PCR-amplified from mouse genomic DNA using the
primers 5′-GCCACACGCGTCCCTCCTCTTGCATTTCA
AAT-3′ and 5′-TCCACAGGATCCTGTTGAAACAATAA
CCTGGAA-3′. pAAV-mIP2-Luc vectors were generated by
replacing the cytomegalovirus promoter of the pAAV-CMV-
Luc plasmid [14] with the mIP2 sequence (bold text indicates
Mlu1 and BamH1 restriction sites). The pAAV-mIP2-emerald
green fluorescent protein (EmGFP) vector was cloned by
replacing the luciferase transgene with EmGFP cDNA.
AAV8 vectors Helper-free AAV8 vector stocks were produced
as previously described [16]. The pRC-2/8 AAV8 capsid-
expressing plasmid was kindly provided by J. Wilson
(University of Pennsylvania, Philadelphia, PA, USA).
AAV vector administrations Mice received an i.p. injection of
AAV8 vectors at a final dose of 2×1011 genome copies per
mouse.
Detection of anti-luciferase antibody Luciferase-expressing
and control 293T cell lysates were separated by SDS-PAGE.
Plasma samples were used as the primary antibody in western
blotting.
IFN-γ ELISpot assay The assay was performed using the
IFN-γ ELISpot Mouse Set (BD Pharmingen, San Diego,
CA, USA). Splenocytes were added to duplicate wells at a
density of 0.1×106, 0.5×106 or 1×106 cells per well along
with DMEM-10 with or without 2.0 μg/ml ovalbumin peptide
or 2.0 μg/ml firefly luciferase epitope peptide. The ovalbumin
T cell-reactive peptide sequence (SIINFEKL) [17] and firefly
luciferase T cell-reactive epitope (LMYRFEEEL) [18] were
synthesised by GenScript (Piscataway, New Jersey, USA).
Immunostaining All immunostaining was conducted as
previously described [16]. Antibodies and the
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concentrations used for immunocytochemistry are described
in the ESM Methods.
Insulitis scoring The insulitis score was determined by fol-
lowing established criteria [19]. Three 7μm thick whole head-
to-tail pancreatic sections (each 200 μm in depth) were col-
lected per animal and co-stained with anti-insulin and anti-
cluster of differentiation 45 (CD45) antibodies, with DAPI
labelling.
Insulin- and glucagon-positive area analysis Pancreatic sec-
tions were prepared and the insulin-positive area was quanti-
fied by using the formula: Percentage insulin-positive area=
insulin-positive area/total tissue area×100 [16].
Mouse pancreatic RNA extraction Pancreases were isolated
and three tissue sections (~20 mg) were immediately proc-
essed using an RNeasy Plus Mini Kit (Qiagen, Limburg,
Netherlands).
RT-PCR and quantitative PCR One microgram of total RNA
was used to synthesise cDNA (EcoDry Premix, Clontech
Laboratories, Mountain View, California, USA).
Quantitative PCR was conducted using SYBR green-based
expression analysis in QuantiTect Primer Assays (Qiagen).
Firefly luciferase expression was determined using SYBR
green quantitative PCR with primers based on a 140 bp seg-
ment of the luciferase gene: Forward FFLuc_qPCR_F, 5′-
GCTATTCTGATTACACCCGAGG-3 ′ ; R ev e r s e
FFLuc_qPCR_R 5′-TCCTCTGACACATAATTCGCC-3′.
Sample size and statistical analysis Groups were compared
by unpaired Student’s t test, and data are expressed as means±
SEM. Significance was set at p<0.05.
Results
Systemic administration of AAV8 vectors containing the mu-
rine insulin 2 promoter facilitates beta cell-targeted transgene
expression AAV8 vectors were engineered to express firefly
luciferase under the control of an internal promoter of the
mouse Ins2 gene (Fig. 1a, ESM Fig. 1a, b). Mice were i.p.
injected with the AAV8 vectors, and luciferase expression was
monitored 2 weeks post infection (p.i.). AAV vectors contain-
ing mIP2 [15] exhibited potent, pancreas-restricted luciferase
expression (Fig. 1b). When the mIP2-AAV8 vector was
used to deliver the EmGFP gene (Fig. 1a), i.p. administra-
tion of AAV8 vectors (2×1011 genome copies/mouse) re-
sulted in selective EmGFP expression in insulin-positive
beta cells (Fig. 1c), demonstrating beta cell-specific trans-
gene expression via the mIP2-AAV8 vector system. When
EmGFP transduction efficiency was assessed from 15 ran-
dom islets, the proportion of EmGFP-positive islet mass
reached up to 66% (average 47.8%), relative to the insulin-
positive area (n=2).
Beta cell targeted luciferase expression induces luciferase-
specific humoral and cellular immune responses Five-week-
old mice (n=4 per time point) were i.p. injected with the
luciferase-expressing mIP2-AAV8 vector (AAV8-Luc).
AAV8-Luc treated and control (PBS-injected) mice were
monitored for luciferase expression (Fig. 2a). Luciferase sig-
nals in the pancreas were observed for 10 weeks p.i.
Expression of beta cell-specific luciferase reached a peak at
around 3 weeks p.i., followed by a dramatic decline in lumi-
nescent signals (Fig. 2a). This correlated well with a marked
decline in luciferase transcripts in the pancreas (Fig. 2b). To
investigate luciferase-specific adaptive immune responses,
plasma samples and splenocytes were harvested and analysed
at 3, 6, 10 and 22 weeks p.i. Three out of four mice showed
weak-to-moderate levels of circulating antibodies against lu-
ciferase by 3 weeks p.i., whereas all mice showed strong
humoral immunity against luciferase by 6 and 10 weeks p.i.
(Fig. 2c). AAV capsid-specific antibody was not detected in
serum (Fig. 2d). Beta cell-targeted luciferase overexpres-
sion also induced potent cellular immunity. An ELISpot
assay revealed a luciferase-specific cytotoxic T lympho-






































Fig. 1 Systemic administration of AAV8 vectors containing mIP2 facil-
itates beta cell-targeted transgene expression. (a) Schematic representa-
tion of AAV vectors. L-ITR, left inverted terminal repeat; R-ITR, right
inverted terminal repeat; prom, promoter. (b) AAV8-mediated luciferase
expression was assessed 14 days after i.p. injection (control n=3, AAV8-
Luc n=3). Luminescence scale bar, ×104. (c) EmGFP expression was
assessed in pancreatic sections EmGFP (n=2). Selective EmGFP expres-
sion (green) was observed in insulin-positive beta cells (red), but not in
acinar cells. Nuclei were counterstained with DAPI (blue). Scale bars,
100 μm
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response reached peak levels between 6 and 10 weeks
p.i., and declined to intermediate levels by 22 weeks
p.i. (Fig. 2e, lower panel).
High-grade islet infiltration by CD4- and CD8-positive T
cells and macrophages was observed in a patient with recent-


























































































































































































Fig. 2 Beta cell-targeted luciferase expression induces specific humoral
and cellular immune responses. (a) Luciferase expression was monitored
3, 6 and 10 weeks p.i. (b) RT-PCR analysis of total pancreatic lysates for
firefly luciferase transcripts in saline controls and AAV8-Luc (white and
black bars, respectively); data represents fold change vs age-matched
controls set as 1; logarithmic scale, base 10; ***p<0.001 vs controls.
(c) Western blot detection of anti-luciferase antibodies in mouse plasma
samples. (d) Lysates from 293T cells overexpressing luciferase and
AAV8 capsid proteins and from uninfected controls were used as an
antigen source to detect antibodies against AAV8 capsid. Plasma samples
were from mice 6 weeks p.i. (n=4). Anti-VP3 antibody was used as a
control. (e) An ELISpot assay was performed to detect cytotoxic T cells
from splenocytes of control (white bars) and AAV8-Luc (black bars)
infected mice that react to the luciferase epitope peptide LMYRFEEEL.
Ovalbumin (OVA) peptide was used as a negative control (grey bars).
Splenocytes were analysed after 3, 6, 10 and 22 weeks. Representative
wells and the means ± SEM of spot-forming units (SFU) from four mice
per group per time point are shown. Logarithmic scale, log base 10. (f)
Representative islets used for insulitis scoring with an anti-CD45 anti-
body at 4 weeks p.i. The table shows the number of random islets counted
and the average (Ave.) intra- and peri-islet CD45 cells (n=3 per group).
(g) Serial pancreatic sections were stained with antibodies against the
immune cell markers CD11b, F4/80, CD4 and CD8 (green). Nuclei were
counterstained with DAPI (blue). Scale bars, 50 μm. INS, insulin; Luc,
luciferase
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the leucocyte common antigen CD45 was performed to detect
inflamed islets, defined as an islet containing more than 15
CD45-positive cells [19].We found 0–5.6% and 57–96% islets
with peri-insulitis or insulitis in control and AAV8-Luc-treated
mice, respectively, at 4 weeks p.i. (Fig. 2f). Further analysis
demonstrated that pancreatic islets were surrounded by
CD11b-positive innate immune cells, murine macrophage
marker (F4/80)-positivemacrophages and CD4-positive helper
T cells as early as 3 weeks p.i. At 6 weeks p.i., there were fewer
CD11b-positive cells, but islets were infiltrated with CD8-
positive CTLs, as well as F4/80- and CD4-positive cells
(Fig. 2g). The timing of CTL infiltration into the islets correlated
with the induction of the luciferase-targeted CTLs (Fig. 2e).
Beta cell targeted immune response results in a transient beta
cel l mass decl ine fol lowed by robust beta cel l
regeneration We next measured the total insulin-positive area
at multiple time points (Fig. 3a, b, ESM Fig. 2a). A significant
decline in beta cell mass was observed 6 weeks post AAV












































































































































































Fig. 3 Beta cell-targeted immune
responses result in a transient
reduction in beta cell mass
followed by robust beta cell
regeneration. (a) Pancreatic islets
were visualised by staining with
anti-glucagon (GCG) and anti-
insulin (INS) antibodies. Images
of the islets at 6 weeks p.i. are
shown. Scale bar, 100 μm. (b)
Insulin-positive area as a
percentage of the total pancreatic
area in treated and control mice
(n=4 for each time point;
*p<0.05, **p<0.01). (c)
Representative pancreatic islets
from AAV8-Luc treated or
control mice stained with anti-
insulin and anti-Ki67 antibodies.
Insulin-positive and Ki67-
positive islet cells from AAV8-
Luc treated or control mice were
counted, and the percentage of
insulin/Ki67 double-positive cells
was determined. Data are
presented as means ± SEM. Scale
bar, 100 μm. *p<0.05 vs control.
(d) Groups of single insulin-
positive and Ki67-positive cells
detected at 10 weeks p.i. are
shown. Scale bars, 100 μm. (e)
Fasting blood glucose levels were
monitored (n=4 per group).
*p<0.05, **p<0.01. (f) Glucose
tolerance test on control and
treated mice (n=4 per group) at
6 weeks p.i. *p<0.05. (g) Fasting
plasma insulin levels were
determined by ELISA at 3 and
10 weeks p.i. (n=3 per group per




Diabetologia (2015) 58:313–323 317
the induction of beta cell-targeted CTLs supports the widely
accepted concept that CD8-positive CTL-mediated beta cell
killing is probably a major mechanism of beta cell destruction
[2]. At 10 weeks p.i., the beta cell mass recovered to normal
levels. By week 22, there was a slight increase in beta cell
mass in damaged islets over control (Fig. 3b).
To assess beta cell regeneration, we counted the number of
insulin-positive, Ki67-positive cells within islets (Fig. 3c, up-
per panels). Beta cell proliferation increased in damaged and
recovering islets at 3 weeks and 10 weeks p.i. by 2.4-fold
(3.03%) and 4.4-fold (0.99%), respectively (Fig. 3c). In addi-
tion, AAV-Luc-treated mouse pancreases frequently showed
groups of single insulin-expressing cells at 10 weeks p.i.,
some of which were also positive for the Ki67 proliferation
marker (Fig. 3d). These observations indicate that robust beta
cell regeneration occurs after immunological destruction in
young mice. Although we found increased apoptotic TUNEL-
positive cells in and around inflamed islets at 3 and 6 week
p.i., most TUNEL-positive cells were not insulin positive
(ESM Fig. 2b).
In the presence of immunological beta cell damage, AAV-
Luc-transduced mice remained normoglycaemic: fasting
blood glucose levels remained <10 mmol/l (Fig. 3e). The only
trend we observed was a moderate decline in fasting blood
glucose levels between weeks 8 and 13. This observation was
also made following expression of another foreign antigen,
ovalbumin, via the mIP2-AAV8 vector (ESM Fig. 3a). Body
weights were the same for mice in both groups (ESM Fig. 3b).
Upon glucose stimulation at 3, 6, 10 and 54 weeks post-AAV
delivery, treated mice responded similarly to controls, but with
slightly faster glucose clearance at 6 weeks p.i. (Fig. 3f, ESM
Fig. 3c). Additionally, transient elevations in circulating insulin
and glucagon-like peptide 1 (GLP-1) were observed during the
immunological attack that occurred at 3 weeks p.i., but not
during beta cell recovery at 10 weeks (Fig. 3g and ESMFig. 3d).
Displacement of glucagon-positive cells and activation of
neurogenin-3-positive cells following immunological beta cell
damage Increased glucagon production and secretion are of-
ten associated with insulin deficiency in type 1 diabetes pa-
tients [21], while the conversion of adult alpha cells to beta
cells has been reported following extreme beta cell loss [22,
23]. We assessed changes in the glucagon-expressing alpha
cell population following immunological beta cell destruction.
Control islets showed a normal distribution of alpha cells
around the perimeter of insulin-positive islets (Fig. 4a). In
contrast, following immunological beta cell injury, we fre-
quently observed an irregular distribution or displacement of
glucagon-positive cells around damaged islets (Fig. 4a, ESM
Fig. 2a). The relative proportion of alpha cells was frequently
increased in inflamed islets at 6 weeks p.i. (Figs 3a and 4a),
with a significant increase in the glucagon-positive area rela-
tive in AAV8-Luc-treated mice (1.67±0.39% and 4.70±
0.91% in control and treated mice, respectively). Alpha cell
displacement was also evident at 10 weeks p.i., with the
frequent appearance of single glucagon-positive cells outside
recovering islets (Fig. 4a).
We also assessed expression of neurogenin 3 (NGN3), the
beta cell progenitor marker. Nuclear NGN3 expression was
evident in all control islets up to 6 weeks (up to age 12 weeks;
Fig. 4b, ESM Fig. 4a). Nuclear NGN3 signals frequently co-
localised with the mature beta cell marker pancreatic and
duodenal homeobox 1 (PDX1) (Fig. 4b right panel, ESM
Fig. 4a), while nuclear NGN3 expression was found in
glucagon-positive alpha cells (ESM Fig. 4b). Strong cytoplas-
mic NGN3 localisation was infrequently observed in cells
around control islets, especially those adjacent to pancreatic
ducts (Fig. 4c, ESM Fig. 4c). These cytoplasmic NGN3-
positive cells did not express insulin or PDX1.
Imaging of NGN3-positive cells in AAV vector-treated
mouse pancreases showed a general decrease in nuclear
NGN3 expression in beta cells and a marked increase in
cytoplasmic NGN3-positive cells in and around the damaged
islets (Fig. 4d, left panel), especially at 6 weeks p.i. (Fig. 4d,
middle panel; ESM Figs 5 and 6). At 10 weeks p.i., cytoplas-
mic NGN3-positive cells were frequently found between the
recovering islets and adjacent ducts (Fig. 4d, right panel,
Fig. 4e, f; ESM Figs 6 and 7). This was accompanied by
induction of PDX1 expression in these ductal cells
(Fig. 4e, f). In contrast to control islets, glucagon-positive
cells were also found at this location (between ducts and islets)
at 10 weeks p.i. (Fig. 4f, ESM Fig. 7), although cytoplasmic
NGN3-positive cells and glucagon-expressing cells formed
distinct populations (Fig. 4g). Single insulin-positive cells
were often found together with cytoplasmic NGN3-positive
cells at 10 weeks p.i. (Fig. 4h).
To confirm our immunohistochemistry results, we conduct-
ed quantitative RT-PCR analysis for key pancreatic genes
(Fig. 4i–p). Changes in expression of the major rodent insulin
gene, Ins2, correlated well with changes in beta cell mass in
the pancreas. Pancreatic expression of Gcg, Pdx1 and Nkx6.1
was comparable between treated and untreated mice. In con-
trast, expression of Ngn3, MafA and NeuroD1, transcription
factors critical for beta cell development, was significantly
elevated 6 and 10 weeks after AAVadministration.
Recruitment of NES- and CD34-positive vascular endothelial
cells to damaged islets Nestin (NES) and CD34 are key
surface markers of neuronal and haematopoietic stem cells
[24, 25]. Previous studies also identified NES-expressing cells
as potential pancreatic progenitor cells [26]. We therefore
assessed changes in NES and CD34 expression in the pancre-
as. Control islets consistently showed NES-positive cells
within the islets and a diffuse distribution around the islet
exterior (ESM Fig. 8a, left panel). During immunological beta
cell damage, there was a dramatic increase in NES-positive
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Time p.i. (weeks) Time p.i. (weeks) Time p.i. (weeks) Time p.i. (weeks)
3 6 10 3 6 10 3 6 10
3 6 10
Time p.i. (weeks) Time p.i. (weeks) Time p.i. (weeks) Time p.i. (weeks)
3 6 10 3 6 10 3 6 10
Fig. 4 Displacement of glucagon-positive cells and activation of NGN3-
positive cells following immunological beta cell damage. (a) The location
of insulin (INS)-positive and glucagon (GCG)-positive cells was deter-
mined by staining control and immunologically damaged islets with anti-
insulin (green) and anti-glucagon (red) antibodies at 3, 6 and 10weeks p.i.
(b) NGN3 expression was detected using an anti-NGN3 antibody in age-
matched control islets at 3 and 6 weeks p.i.. Note cytoplasmic (arrows)
and nuclear localisation (arrowheads) in normal islets. (c) Immunostain-
ing demonstrated both nuclear (arrowheads) and cytoplasmic (arrow)
NGN3 expression in age-matched control islets near ducts. (d) NGN3
expressionwas analysed in islets fromAAV8-Luc-transduced mice at 3, 6
and 10 weeks p.i. Insulin expression was detected using an anti-insulin
antibody. (e) Islets from AAV8-Luc-transduced mice at 6 weeks p.i. were
analysed for NGN3 and PDX1 (green) expression. Note induction of
PDX1 expression in ductal lining cells (arrows). (f) Representative islets
showing NGN3, PDX1 and glucagon localisation after immune response.
Nuclear PDX1-positive cells (arrows) were identified in ductal lining
cells. (g) Immunostaining of the region between recovering islets and
ducts with anti-NGN3 and glucagon antibodies. (h) A representative
image of single insulin-positive cells (green) identified at 10 weeks p.i.
is shown with anti-NGN3 co-staining (red). (a–h) Dashed lines corre-
spond to ductal epithelium. Scale bars, 50 μm; w, weeks. (i–p) Quanti-
tative RT-PCR analysis of pancreatic transcripts for common islet- and
beta cell-associated factors. Results show AAV8-Luc transcripts (black
bars) relative to age-matched control (white bars) pancreas, set as 1;
logarithmic scale, base 10. Data are presented as means ± SEM,
representing four mice per group per time point. *p<0.05, **p<0.01,
***p<0.001; INS, insulin
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cells around islets (ESM Fig. 8a, centre and right panels).
Although pancreatic stellate cells have been reported to express
NES and glial fibrillary acidic protein (GFAP) during pancre-
atic inflammation [27], we found NES and GFAP staining in
the same location, but not necessarily in the same cells (ESM
Fig. 8a, right panel). Quantitative RT-PCR analysis showed
increased levels of Nes transcripts in inflamed pancreas at
3 weeks p.i. (ESM Fig. 8b). Recruitment of CD34-positive
cells was evident at the same time point (ESM Fig. 8c).
Indeed, many NES-positive cells in and around damaged islets
were also positive for CD34 and endoglin (CD105; ESM
Fig. 8d), suggesting that NES/CD34 double-positive cells are
vascular endothelial cells. Some NES-positive cells did not
express CD34 or CD105 (ESM Fig. 8d). Similar to the biased
distribution of NGN3- and glucagon-positive cells during islet
recovery, more NES-positive cells were found between recov-
ering islets and ducts at 10 weeks p.i. (ESM Fig. 8e), although
the NES-positive cells were distinct from glucagon- and
NGN3-expressing cells (ESM Fig. 8e, f). We also induced
immunological beta cell damage in a NES-positive cell lineage
tracingmouse model (ESMFig. 8g). A subset of acinar cells, as
well as vascular endothelial-like cells, was labelled with mem-
brane EmGFP (mGFP) in control and insulitis-induced mice
(ESM Fig. 8g). There were no mGFP-positive beta cells, thus
ruling out a direct contribution of NES-positive cells to beta cell
development and regeneration.
Induced immunological beta cell destruction leads to beta cell
regeneration in aged mice One-year-old mice (n=6 per treat-
ment) were i.p. injected with AAV8-Luc, and monitored for
luciferase expression. Luciferase signals in the pancreas
reached a peak at around 3 weeks p.i., followed by a marked
decline by 10 weeks p.i. (ESM Fig. 9), which correlated with
notable immune infiltration in treated islets (ESM Fig. 10a).
Upon immunological beta cell destruction in aged mice, sim-
ilar trends were observed in terms of induction of NES- or
NGN3-positive cells (Fig. 5a, ESM Fig. 10b), reduced beta
cell mass (Fig. 5b) and increased insulin-positive cell
e
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Fig. 5 Induced immunological
beta cell destruction leads to beta
cell regeneration in aged mice. (a)
Mice received AAV8-Luc vector
through i.p. injection.
Immunohistochemistry was
performed at 6 and 10 weeks p.i.
Scale bars, 50 μm. (b) Percentage
insulin-positive area was
determined as described in Fig. 3b.
(c) Beta cell proliferation was
determined as described in Fig. 3c.
Images of islets at 6 weeks are
shown. Beta cell proliferation was
determined by quantification of
total insulin- and Ki67-positive
cells in five random islets from
age-matched controls (n=4 per
time point) and AAV8-Luc-
transduced mice (n=4 per time
point). *p<0.05 vs control. (d) A
representative islet in AAV8-Luc-
treated mice at 10 weeks p.i.,
showing a dense population of
Ki67-positive cells with a few
isolated insulin-positive and Ki67-
positive cells. (e) Fasting blood
glucose levels were determined
over the 10 week period for treated
(n=4) and control mice (n=4).
**p<0.01 vs control. (f) Glucose
tolerance tests were conducted at
5 weeks p.i. when vector-treated
mice showed higher fasting blood
glucose levels (see Fig. 5e). GCG,
glucagon; INS, insulin; (b, c, e, f)
white bars/squares, saline controls;
black bars/squares, AAV8-Luc
treatment
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proliferation (Fig. 5c). Additionally, groups of single insulin-
expressing cells, some expressing Ki67, were observed at
10 weeks p.i. (Fig. 5d, ESM Fig. 11). Although these obser-
vations demonstrate the robust regenerative capacity of beta
cells following immunological damage in aged mice, many
recovering islets initially exhibited notable scarring (Fig. 5a,
ESM Fig. 10), and there were temporary fluctuations in blood
glucose levels (Fig. 5e, f). Those observations suggest that
beta cell repair responses are slower in aged mice than in their
younger counterparts.
Discussion
We used a beta cell-targeting AAV8 vector to induce single-
round expression of a target antigen, firefly luciferase, in pre-
existing beta cells. In this model, newly regenerated beta cells
do not express the target antigen, thus allowing visualisation of
beta cell recovery following immunological beta cell destruc-
tion. Luciferase expression also allowed non-invasive live
imaging of beta cells under immunological attack. Since
AAV vectors have broad host ranges, our ‘hit-and-run’ antigen
transduction system can be used to induce immunological beta
cell injury in various animal species, including rodents, large
animal models and non-human primates, with particular
genetic backgrounds and ageing status. It is plausible that
immunological beta cell destruction in mice with a high-risk
type 1 diabetes genetic background can lead to full-blown
autoimmune diabetes. In addition, the use of different AAV
serotype vectors, such as AAV8 and AAV9, with beta cell
tropism [15, 16, 28, 29] would allow multiple rounds of vector
administration to beta cells, providing an opportunity to assess
the contribution of environmental triggers and the long-term
influence of multiple asymptomatic immune events on beta
cell proliferative capability in animal models.
Beta cell proliferation is increasingly recognised as a pri-
mary pathway for beta cell expansion during normal postnatal
development, pregnancy, or following partial pancreatectomy
or partial beta cell ablation [30–33]. Here, we found robust
beta cell proliferation following immunological beta cell de-
struction in young mice. Increased beta cell proliferation was
evident as early as 3 weeks p.i. (Fig. 3c, d), when luciferase-
targeted humoral, but not cellular, immunity was detectable
(Fig. 2e), and until replenishment of the beta cell mass at
10 weeks p.i. Although their beta cell mass recovery was
slower, aged mice also demonstrated significantly increased
beta cell proliferation after immunological beta cell destruc-
tion. Our data therefore suggest that beta cell proliferation is
the primary mode of beta cell regeneration following immu-
nological beta cell destruction, consistent with previous stud-
ies demonstrating increased beta cell proliferation in recent-
onset type 1 diabetic patients [4, 20].
Various cell types have been proposed as potential progen-
itors of beta cells [34]. For instance, partial duct ligation
(PDL) induces PDX1 expression in duct-lining cells and
mobilises NGN3-positive cells, which can give rise to beta
cells [35, 36]. The conversion of adult alpha cells to beta cells
has also been demonstrated after extreme beta cell loss [22]. In
our study, immune-mediated beta cell destruction frequently
led to alpha cell mass increase and displacement, confirming
previous studies in type 1 diabetic patients or in NOD mice
with immunological beta cell damage [4, 23]. Groups of
glucagon-positive cells were also found between recovering
islets and adjacent ducts at 10 weeks p.i. Similarly, increased
numbers of cytoplasmic NGN3-positive cells were found
around damaged and recovering islets, with PDX1 induction
in ductal cells near to recovering islets. At present, it is not
known whether those cells can directly differentiate into beta
cells. Recently, Xiao et al (2013) showed increased NGN3
expression in proliferating ductal cells and existing beta cells
after PDL but that these cells do not directly contribute to beta
cell neogenesis [30]. Considering that beta cell proliferation
starts at 3 weeks p.i. and notable recruitment and activation of
alpha cells and cytoplasmic NGN3-positive cells is initiated at
later time points, it is less likely that alpha cells and cytoplas-
mic NGN3-positive cells play primary roles in beta cell re-
generation, at least in the early stage of beta cell regeneration
after immunological beta cell destruction. Since beta cell
injury can activate alpha cells to produce GLP-1, a growth
and survival factor for beta cells [23], it is plausible that alpha
cells indirectly support beta cell recovery through a paracrine
action. Combinations of genetic lineage tracing studies using
our AAV8-mIP-Luc vector-mediated immunological destruc-
tion model would reveal whether specific cell types act as beta
cell progenitors following immunological beta cell
destruction.
NES-positive cells were initially recognised as multipoten-
tial stem cells in the adult pancreas [26]. Immunological beta
cell damage induced the rapid expansion, and potentially the
recruitment, of NES-positive cells in and around damaged
islets. Nevertheless, our lineage tracing experiment demon-
strated that NES-positive cells contribute to exocrine and
microvasculature cells, but not to beta cells, supporting a
previous report [37]. Our preliminary data using the AAV8-
mIP2-Luc vector in NES knockout mice suggest roles for
NES-positive endothelial cells in the recruitment of CD11b-
positive immune cells to damaged islets and in the clearance
of apoptotic beta cells from damaged islets (J. M. Tonne and
Y. Ikeda, unpublished data). Further study should shed light
on the role of the NES-positive cells in type 1 diabetes
pathogenesis.
Another notable finding is that immunological beta cell
destruction induces responses reminiscent of those reported
in the PDL mouse model [35, 36], such as induction of ductal
PDX1 expression, activation of NGN3-positive cells and
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recruitment of NES-positive cells. It is conceivable that im-
munological beta cell damage and physical injury to the
pancreas activate a conserved beta cell recovery process.
In conclusion, we have demonstrated that the beta cell-
targeted AAV8 vector can induce immunological beta cell
destruction. Our results validate the use of this system as a
tool to induce single-round beta cell destruction as well as
visualising beta cell regeneration after immunological abla-
tion. Our model provides a valuable platform to characterise
beta cell regeneration after immunological destruction in var-
ious animal models with different genetic backgrounds and
ageing status.
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